30
https://pubmed.ncbi.nlm.nih.gov/38092951
The abstract reports a systematic review and updated guidelines by the European Society of Urogenital Radiology Contrast Media Safety Committee, stating that while there is limited evidence on the relationship between iodine-based contrast media and myasthenia gravis symptoms, the vast majority of myasthenia gravis patients experience no increased severity of symptoms after contrast media administration, although a small risk of increased symptoms within 24 hours after administration may exist for less than 5% of patients.